Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole. 

By Amy Baxter • Aug. 18, 2025

Biopharma layoffs rise as drugmakers tighten belts and reorganize

Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.

By Kelly Bilodeau • Aug. 18, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

With scrapped mRNA funding, a vaccine maker finds a silver lining

While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.

By Michael Gibney • Aug. 14, 2025

With FDA PreCheck, drugmakers may get a manufacturing boost

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

By Amy Baxter • Aug. 13, 2025

3 ways the GLP-1 market has changed shape this year

Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.

By Amy Baxter • Aug. 12, 2025

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

By Michael Gibney • Aug. 12, 2025

Are stem cell therapies ready for pharma’s prime time?

Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.

By Kelly Bilodeau • Aug. 11, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Inside AstraZeneca’s long-game strategy in lung cancer

New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

By Michael Gibney • Aug. 7, 2025

PBM reform was dropped from Trump’s spending bill. It could have saved billions.

The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.

By Alexandra Pecci • Aug. 6, 2025

David Altshuler, geneticist who helped transform Vertex, to retire next year

Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”

By Ben Fidler • Aug. 5, 2025

Let’s make a deal? Big Pharma execs express varying views on their M&A future

Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

By Michael Gibney • Aug. 5, 2025

Drugmakers score policy win in a prolonged fight against 340B

A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.

By Amy Baxter • Aug. 4, 2025

Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.

By Michael Gibney • Aug. 1, 2025

C-suite shuffles ripple through pharma

Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.

By Meagan Parrish • July 31, 2025

Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

By Ben Fidler • July 30, 2025

Roche pushes ahead with late-comer strategy in obesity

The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.

By Amy Baxter • July 30, 2025

Could bispecifics unseat Keytruda from its oncology throne?

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

By Kelly Bilodeau • July 28, 2025

From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

The studies are contributing preclinical advances for some of the world’s biggest blockbusters.

By Michael Gibney • July 25, 2025

Pharma’s turbo spending spree on US manufacturing

The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.

By Meagan Parrish • July 24, 2025

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

By Alexandra Pecci • July 24, 2025

Who is Dr. George Tidmarsh, the new director of CDER?

Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

By Meagan Parrish and Michael Gibney • July 23, 2025

Novartis’ Zolgensma sales fall again as gene therapy market woes persist

Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?

By Michael Gibney • July 22, 2025

3 major patent losses this year — and a key strategy to fill the gaps

Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.

By Kelly Bilodeau • July 21, 2025